ViaDerma Inc (VDRM)

[PhenixBleu]

The President of Kasten, Inc. is James Cahill. Keough is the COO and President.

Keough was the CEO of OPD Holdings aka Thru Pharma and Dakota Life Sciences prior to the completion of their merger with Kasten.

Keough was a CEO when he hired ViaDerma's CEO, Christopher Ayo Otiko, to work on his proprietary projects. Then Otiko took what he learned through his work and started ViaDerma using Keough's trademarked technology. Otiko referred to Diabecline as ViaDerma's Lead Product on the VDRM website after executing a contract that states he would never compete. He went so far as to claim the 2012 Edison Award for Diabecline was an Award given to ViaDerma. Again, Keough owns the Trademark on Diabecline, and the underlying technology that he claims Otiko used in his 2017 Provisional Patent Applications.

Keough has no known alias.

Why in the world would an outstanding IP Lawyer who is CEO of Kast need an alias?